Description
Key facts
Cell type:HCT116,
Species or organism:Human,
Tissue:Colon,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon2.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GNA13, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GNA13 also known as Gα13 is a member of the G12 family of G proteins. It has a molecular mass of approximately 44 kDa and functions as a guanine nucleotide-binding protein. This protein is important in transmitting signals from G protein-coupled receptors (GPCRs) to intracellular signaling pathways. GNA13 is widely expressed in various tissues including endothelial cells smooth muscle cells and the brain. The signaling capability of GNA13 is based on its ability to bind GTP and GDP functioning through a cycle of activation and inactivation.
Biological function summary
The role of G protein subunit GNA13 involves participating in critical cellular functions such as cytoskeletal reorganization cell migration and proliferation. It is an integral part of the G12/G13 subunits` complex which plays a role in controlling cell dynamics and morphology. Through these activities GNA13 contributes to the regulation of processes like embryonic development and tissue repair. Additionally it influences cell behavior through the RhoA pathway affecting actin cytoskeleton and cell shape changes.
Pathways
GNA13 interacts with a variety of important signaling systems. One primary pathway where GNA13 is active is the Rho signaling pathway where it activates RhoA leading to changes in the actin cytoskeleton. This pathway is necessary for cellular processes like adhesion and motility. Additionally GNA13 participates in the mitogen-activated protein kinase (MAPK) pathway influencing cellular proliferation. Through these pathways GNA13 is related to proteins such as RhoGEFs which act as guanine nucleotide exchange factors and MAPKs essential in transmitting mitogenic signals.
GNA13 has implications in cancer development and cardiovascular diseases. Its role in Rho signaling and cell motility can contribute to tumor progression and metastasis with alterations in its function linked to various cancers. Additionally in cardiovascular health GNA13's influence on vascular smooth muscle contraction can relate to conditions such as hypertension. Projecting its influence through RhoA GNA13's malfunction connects it to pathological changes within these disease contexts.
